In the case of Daikin Industries Ltd. v. Assistant Controller of Patents and Designs, the Indian Patent Office refused Daikin’s patent application relating to a shell and plate heat exchanger on the ground of lack of novelty over a prior art document. During the appeal before the High Court, Daikin sought permission to amend claim 1 by incorporating additional limitations already disclosed in the specification. The court examined whether such an amendment could be permitted at the appellate stage under Section 59 of the Patents Act.
Read more about Amendment of claims at Appellate Stage under section 59 of the Patents ActTag: Patent Law india
Court Remands Patent Rejection Over IV Catheter, Cites Flawed Obviousness Test
Delhi HC sets aside patent rejection for IV catheter, citing flawed inventive step analysis under Agriboard test and lack of reasoned decision.
Read more about Court Remands Patent Rejection Over IV Catheter, Cites Flawed Obviousness TestCannot raise new ground while refusing patent, rules Delhi High Court
Delhi HC set aside a patent refusal against Proprietect L P, citing violation of natural justice, failure to consider amended claims, and lack of reasoning.
Read more about Cannot raise new ground while refusing patent, rules Delhi High CourtDelhi High Court Patent Injunction: Aquestia Wins Against Automat Industries
Delhi High Court grants patent injunction to Aquestia, stopping Automat from selling Hydromat valves over suspected patent infringement.
Read more about Delhi High Court Patent Injunction: Aquestia Wins Against Automat IndustriesPatented But Still Infringing: Delhi HC Stops Hydromat Valve Sales
In the case of Aquestia Limited vs Automat Industries Private Limited & Ors., the Delhi High Court granted an interim injunction restraining the defendants from manufacturing and selling their ‘Hydromat’ valves. The court held that even a patented product can infringe an earlier patent, and found that the defendants’ valves incorporated the core features of the plaintiff’s fluid control valve patent claims.
Read more about Patented But Still Infringing: Delhi HC Stops Hydromat Valve SalesPatented Biologics and Section 104A: No Process Disclosure Without Proving Product Identity
Roche sued Zydus for infringing its process patent on Pertuzumab. The Delhi High Court held that Roche had not shown Zydus’s biosimilar was identical to its product. Without identity, Section 104A did not apply, and the Court refused to compel Zydus to disclose its manufacturing process.
Read more about Patented Biologics and Section 104A: No Process Disclosure Without Proving Product IdentityIndian Patent Office Issues Draft CRI Guidelines 2025 – Version 2.0: Key Additions and Changes
Version 2.0 of the Draft CRI Guidelines 2025 introduces updated examination procedures for AI, blockchain, and quantum-based inventions, and includes an extensive annexure of examples clarifying Section 3(k) exclusions.
Read more about Indian Patent Office Issues Draft CRI Guidelines 2025 – Version 2.0: Key Additions and ChangesITC’s Nicotine Device Patent Rejection on Public Health Grounds Set Aside
The Calcutta High Court has set aside the refusal of ITC’s patent application for a nicotine aerosol device. The Court found that the Controller’s reliance on morality grounds under Section 3(b) was improper and unsupported by cited documents, ensuring a fresh review of the patent.
Read more about ITC’s Nicotine Device Patent Rejection on Public Health Grounds Set AsidePatent for Enzyme-Based Animal Feed Supplementation Cleared of Section 3(i) Refusal
The Madras High Court has allowed Kemin Industries’ patent on an enzyme-based animal feed method, overturning the Controller’s Section 3(i) refusal. The Court ruled that the method involves feed supplementation rather than treatment, confirming novelty and inventive step in the process.
Read more about Patent for Enzyme-Based Animal Feed Supplementation Cleared of Section 3(i) RefusalAnti-Cancer Patent Refusal Set Aside for Not Identifying ‘Known Substance’
In a recent ruling, the Delhi High Court overturned the rejection of an anti-cancer patent filed by Taiho Pharmaceutical. The Court highlighted that objections under Section 3(d) must explicitly state the “known substance” being referenced and directed a fresh hearing for proper assessment.
Read more about Anti-Cancer Patent Refusal Set Aside for Not Identifying ‘Known Substance’